# Sublingual Oxytocin for the Prevention of Post-partum Hemorrhage

> **NCT06968481** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Insud Pharma** · enrollment: 330 (estimated)

## Conditions studied

- Post Partum Hemorrhage

## Interventions

- **DRUG:** Oxytocin sublingual
- **DRUG:** Oxytocin IM

## Key facts

- **NCT ID:** NCT06968481
- **Lead sponsor:** Insud Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-30
- **Primary completion:** 2026-10-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06968481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06968481, "Sublingual Oxytocin for the Prevention of Post-partum Hemorrhage". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06968481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*